Skip to main content

Table 2 Short–term (six–months) mortality rates and rates ratios by comorbidity status, sex, age, smoking status, province of residence, BMI, surgery, cancer histology, and TNM stage among lung cancer patients diagnosed between 2010 and 2012, in two population-based Spanish cancer registries: Girona and Granada (n = 1259 lung cancer patients and 581 deaths at six–month after cancer diagnosis)

From: The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study

Variables

Deaths / PM

MR per 100 PM (95% CI)

MRR

(95% CI)

P–value

RCS-modified Charlson score

   

< 0.001*

 No comorbidity

196 / 2166

9.0 (7.9–10.4)

Ref.

 

 One comorbidity

164 / 1526

10.7 (9.2–12.5)

1.2 (1.0–1.5)

 

 Two or more comorbidities

221 / 1698

13.0 (11.4–14.8)

1.4 (1.2–1.7)

 

Sex

   

0.009

 Male

502 / 4435

11.3 (10.4–12.4)

Ref.

 

 Female

79 / 956

8.3 (6.6–10.3)

1.4 (1.1–1.7)

 

Age at diagnosis (years)

   

< 0.001*

  < 60

108 / 1470

7.3 (6.1–8.9)

Ref.

 

 60–69

131 / 1569

8.3 (7.0–9.9)

1.1 (0.9–1.5)

 

 70–79

181 / 1630

11.1 (9.6–12.8)

1.5 (1.2–1.9)

 

  ≥ 80

161 / 721

22.3 (19.1–26.1)

3.0 (2.4–3.9)

 

Smoking status at diagnosis

   

0.176

 Never smoked

53 / 687

7.7 (5.9–10.1)

Ref.

 

 Previous smoker

222 / 2199

10.1 (8.9–11.5)

1.3 (1.0–1.8)

 

 Current smoker

204 / 2002

10.2 (8.9–11.7)

1.3 (1.0–1.8)

 

Province

   

< 0.001

 Girona

189 / 2274

8.3 (7.2–9.6)

Ref.

 

 Granada

392 / 3116

12.6 (11.4–13.9)

1.5 (1.3–1.8)

 

Body Mass Index (kg/m2)

   

0.101*

 Healthy weight (< 25.0)

96 / 1551

6.2 (5.1–7.6)

Ref.

 

 Overweight (25.0–29.9)

82 / 1427

5.7 (4.6–7.1)

0.9 (0.7–1.2)

 

 Obese (≥30)

40 / 796

5.0 (3.7–6.9)

0.8 (0.6–1.2)

 

Surgery

   

< 0.001

 Yes

8 / 1216

0.7 (0.3–1.3)

Ref.

 

 No

541 / 4084

13.2 (12.2–14.4)

20.1 (10.0–40.5)

 

Histology

   

0.002

 ADE

152 / 1800

8.4 (7.2–9.9)

Ref.

 

 Others

247 / 1215

20.3 (17.9–23.0)

2.4 (2.0–2.9)

 

 SCLC

66 / 715

9.2 (7.3–11.8)

1.1 (0.8–1.5)

 

 SQUA

116 / 1654

7.0 (5.8–8.4)

0.8 (0.7–1.1)

 

TNM stage

   

< 0.001

 I–III (No-metastasis)

143 / 2810

5.1 (4.3–6.0)

Ref.

 

 IV (Metastasis)

398 / 2474

16.1 (14.6–17.8)

3.2 (2.6–3.8)

 
  1. * Test for trend p-value
  2. CI: Confidence Interval; MR: Mortality Rate; MRR: Mortality Rate Ratio; PM: Person–month;
  3. Histology: ADE: adenocarcinoma; SCLC: small cell lung cancer; SQUA: Squamous carcinoma; Others: non-small cell lung cancer, large cell lung cancer, neuroendocrine lung cancer, and unspecified lung cancer